Targeting the apoptosis pathway in prostate cancer

Cancer Journal (United States)

Volumn 19, Issue 1, 2013, Pages 79-89

  Zielinski, Robert R ^a   Eigl, Bernhard J ^a   Chi, Kim N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

apoptosis; Metastatic prostate cancer; programmed cell death

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 236; AEG 35156; ANTINEOPLASTIC AGENT; AT 406; BH3 PROTEIN; BI 97C 1; BIM PROTEIN; BIRINAPANT; CASPASE; CHAPERONE; CLUSTERIN; CUSTIRSEN; DEATH RECEPTOR; DEATH RECEPTOR 5; FAS ANTIGEN; GATAPARSEN; GDC 0152; GOSSYPOL; HGS 1029; INHIBITOR OF APOPTOSIS PROTEIN; ISOSORBIDE; LCL 161; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SEPANTRONIUM BROMIDE; SGI 1176; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TW 37; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTISENSE THERAPY; APOPTOSIS; BLOOD TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL HYPOXIA; CELL PROTECTION; CELL SURVIVAL; CYTOTOXICITY; DNA DAMAGE; DRUG INHIBITION; ENZYME ACTIVITY; FATIGUE; HUMAN; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HEAT-SHOCK PROTEINS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84873853968     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182801cf7     Document Type: Review

References (108)

1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364: 1995-2005.
2. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazi-taxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunother-apy for castration-resistant prostate cancer. N Engl J Med. 2010;363: 411-422.
4. Parker C, Heinrich D, Sartor AO, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase II randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(suppl 5). Abstract 8).
5. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012.
6. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19:62-71.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
8. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25: 805-813.
9. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004;64:6595-6602.
10. Miyake H, Nelson C, Rennie PS. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to andro-gen independence in prostate cancer. Cancer Res. 2000;60:170-176.
11. Miyake H, Tolcher A, Gleave ME. Antisense Bcl-2 oligodeoxynucleo-tides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res. 1999;59:4030-4034.
12. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
13. Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and Bcl-2. Nature. 1990;348:331-333.
14. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281: 1309-1312.
15. Spierings D, McStay G, Saleh M, et al. Connected to death: the (unex-purgated) mitochondrial pathway of apoptosis. Science. 2005;310: 66-67.
16. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205-219.
17. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590-8607.
18. Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 2010;11:699-707.
19. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-629.
20. Jiang X, Wang X. Cytochrome cYmediated apoptosis. Annu Rev Bio-chem. 2004;73:87-106.
21. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5:189-200.
22. Sheridan C, Martin SJ. Commitment in apoptosis: slightly dead but mostly alive. Trends Cell Biol. 2008;18:353-357.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
24. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006;103:14907-14912.
25. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153-164.
26. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell. 2003;3: 17-22.
27. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
28. Nastiuk KL, Krolewski JJ. FLIP-ping out: death receptor signaling in the prostate. Cancer Biol Ther. 2008;7:1171-1179.
29. Cornforth AN, Davis JS, Khanifar E, et al. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene. 2008;27:4422-4433.
30. Cronauer MV, Schulz WA, Burchardt T, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling [review]. Int J Oncol. 2003;23: 1095-1102.
31. Sun A, Tang J, Hong Y, et al. Androgen receptorYdependent regulation of Bcl-xL expression: implication in prostate cancer progression. Prostate. 2008;68:453-461.
32. van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 2006;16:203-213.
33. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimer-sen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:1264-1269.
34. Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009;15:3172-3176.
35. Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012; 23:1803-1808.
36. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obato-clax (GX15-070) antagonizes Mcl-1 and overcomes Mcl-1Ymediated resistance to apoptosis. Proc Natl Acad Sci USA. 2007;104: 19512-19517.
37. Dash R, Azab B, Quinn BA, et al. Apogossypol derivative BI-97C1 (sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to MDA-7/IL-24Ymediated toxicity. Proc Natl Acad Sci USA. 2011;108: 8785-8790.
38. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567-1576.
39. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer. 2005;113: 619-628.
40. Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12(20 pt 1):6116-6124.
41. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 2007;13:3585-3590.
42. Kitada S, Kress CL, Krajewska M, et al. Bcl-2 antagonist apogossy-pol (NSC736630) displays single-agent activity in Bcl-2Ytransgenic mice and has superior efficacy with less toxicity compared with gossy-pol (NSC19048). Blood. 2008;111:3211-3219.
43. Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res. 2007;13:2226-2235.
44. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to Bcl2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488-496.
45. Zhai D, Jin C, Satterthwait AC, et al. Comparison of chemical inhibitors of antiapoptotic Bcl-2Yfamily proteins. Cell Death Differ. 2006;13: 1419-1421.
46. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29:909-916.
47. Bova GS, MacGrogan D, Levy A, et al. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996;35:46-54.
48. Sanlioglu AD, Koksal IT, Ciftcioglu A, et al. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol. 2007;177:359-364.
49. National Institutes of Health. Safety of SGI-1776, a PIM kinase inhibitor in refractory prostate cancer and relapsed/refractory non Hodgkin's ymphoma. Available at: http://clinicaltrials.gov/ct2/show/NCT00848601.
50. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
51. Sikic BI, Wakelee HA, von Mehren M, et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxo-rubicin or FOLFIRI. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25:18S. Supplement 14006.
52. Nastiuk KL, Kim JW, Mann M, et al. Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate. J Cell Physiol. 2003;196:386-393.
53. Wright ME, Han DK, Hockenbery DM. Caspase-3 and inhibitor of apoptosis protein(s) interactions in Saccharomyces cerevisiae and mammalian cells. FEBS Lett. 2000;481:13-18.
54. Mehrotra S, Languino LR, Raskett CM, et al. IAP regulation of metastasis. Cancer Cell. 2010;17:53-64.
55. Yang L, Cao Z, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res. 2003;63:6815-6824.
56. McManus DC, Lefebvre CA, Cherton-Horvat G, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004; 23:8105-8117.
57. Jackson RS 2nd, Placzek W, Fernandez A, et al. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xeno-graft models of prostate cancer. Neoplasia. 2012;14:656-665.
58. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435: 677-681.
59. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421-3428.
60. Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inacti-vation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571:43-49.
61. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates Bad on serine 112 and reverses Bad-induced cell death. J Biol Chem. 2003;278:45358-45367.
62. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001;108: 965-969.
63. LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apopto-sis (IAPs) and their emerging role in cancer. Oncogene. 1998;17: 3247-3259.
64. Dean E, Jodrell D, Connolly K, et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol. 2009;27: 1660-1666.
65. Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonu-cleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009;27:4741-4746.
66. Schimmer AD, Herr W, Hanel M, et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk. 2011;11:433-438.
67. Mahadevan D, Chalasani P, Rensvold D, et al. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol. 2012.
68. Sikic BI, Eckhardt SG, Gallant G, et al. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: results of a phase I study. J Clin Oncol. 2011;29 (suppl; abstract 3008).
69. Zhang M, Latham DE, Delaney MA, et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24: 2474-2482.
70. Lens SM, Vader G, Medema RH. The case for survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18:616-622.
71. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18: 609-615.
72. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535-1542.
73. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, sur-vivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
74. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, cas-pases, and anticancer drugs. Cancer Res. 1998;58:5315-5320.
75. Mahotka C, Wenzel M, Springer E, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097-6102.
76. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120-128.
77. Wiechno PJ, Chlosta P, Smok-Kalwat J, et al. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). J Clin Oncol. 2011;29: (suppl; abstract 4592).
78. Talbot DC, Davies J, Olsen A, et al. Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. J Clin Oncol. 2009;27:15s (suppl; abstract 3507).
79. Tolcher AW, Papadopoulos K, Patnaik A. Phase I/II open-label study of YM-155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC). 2009 Genitourinary Cancers Symposium. J Clin Oncol. 2009. Abstract 214.
80. Tolcher AW, Quinn DI, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012;23:968-973.
81. National Institutes of Health. Dose escalation study of safety and toler-ability of AT-406 in patients with advanced solid tumors and lym-phomas. Available at: http://clinicaltrials.gov/ct2/show/NCT01078649.
82. National Institutes of Health. A study of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors. Available at: http://clinicaltrials.gov/ct2/show/NCT01240655.
83. Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007;67:10455-10465.
84. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764.
85. Hotte SJ, Yu EY, Hirte HW, et al. Phase I trial of OGX-427, a 2¶ meth-oxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (HSP27): final results. J Clin Oncol. 2010;28:15s (suppl; abstract 3077).
86. Chi KN, Hotte SJ, Ellard S, et al. A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). J Clin Oncol. 2012;30:(suppl; abstract 4514).
87. National Institutes of Health. OGX-427 in metastatic castrate-resistant prostate cancer with prostate-specific antigen progression while receiving abiraterone. Available at: http://clinicaltrials.gov/ct2/show/NCT01681433.
88. Miyake H, Nelson C, Rennie PS, et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 2000;60:2547-2554.
89. Sensibar JA, Sutkowski DM, Raffo A. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated gylocprotein-2 (clusterin). Cancer Res. 1995;55:2431-2437.
90. Zellweger T, Chi K, Miyake H. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002;8:3276-3284.
91. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynu-cleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2000;6: 1655-1663.
92. July LV, Beraldi E, So A. Nucleotide-based therapies targeting clus-terin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223-232.
93. Miyake H, Gleave ME, Kamidono S. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology. 2002;59:150-154.
94. Zhang H, Kim JK, Edwards CA, et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909-915.
95. Trougakos IP, Lourda M, Antonelou MH, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res. 2009;15:48-59.
96. Zhong B, Sallman DA, Gilvary DL, et al. Induction of clusterin by AKTYrole in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther. 2010;9:1831-1841.
97. Ammar H, Closset JL. Clusterin activates survival through the phosphati-dylinositol 3-kinase/Akt pathway. J Biol Chem. 2008;283:12851-12861.
98. Zoubeidi A, Ettinger S, Beraldi E, et al. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res. 2010;8:119-130.
99. Carver JA, Rekas A, Thorn DC, et al. Small heat-shock proteins and clusterin: intra-and extracellular molecular chaperones with a common mechanism of action and function? IUBMB Life. 2003;55:661-668.
100. Nizard P, Tetley S, Le Drean Y, et al. Stress-induced retrotranslocation of clusterin/ApoJ into the cytosol. Traffic. 2007;8:554-565.
101. Zellweger T, Miyake H, Cooper S. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2¶-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther. 2001;298:934-940.
102. Sowery RD, Hadaschik BA, So AI, et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 2008;102: 389-397.
103. Saad F, Hotte S, North S, et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06c. Clin Cancer Res. 2011;17:5765-5773.
104. Chi K, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2¶ meth-oxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res. 2008; 14:833-839.
105. Chi K, Hotte SJ, Yu EY, et al. Randomized phase II study of doce-taxel and prednisone with or without OGX-011 in patients with meta-static castration-resistant prostate cancer. J Clin Oncol. 2010;28: 4247-4254.
106. Chi K, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2¶ methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287-1296.
107. National Institutes of Health. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY). Available at: http://clinicaltrials.gov/ct2/show/NCT01188187.
108. National Institutes of Health. Comparison of cabazitaxel/prednisone alone or in combination with custirsen for 2nd line chemotherapy in prostate cancer (AFFINITY). Available at: http://clinicaltrials.gov/ct2/show/NCT01578655.